國立虎尾科技大學 |

Interaction of mycophenolic acid and pantoprazole = a pharmacokinetic crossover study /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Interaction of mycophenolic acid and pantoprazole/ by Olesja Rissling.
Reminder of title:	a pharmacokinetic crossover study /
Author:	Rissling, Olesja.
Published:	Wiesbaden :Springer Fachmedien Wiesbaden : : 2017.,
Description:	xxii, 162 p. :ill. (some col.), digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Mycophenolic acid. -
Online resource:	http://dx.doi.org/10.1007/978-3-658-19889-3
ISBN:	9783658198893

Interaction of mycophenolic acid and pantoprazole = a pharmacokinetic crossover study /
Rissling, Olesja.

Interaction of mycophenolic acid and pantoprazolea pharmacokinetic crossover study /[electronic resource] :by Olesja Rissling. - Wiesbaden :Springer Fachmedien Wiesbaden :2017. - xxii, 162 p. :ill. (some col.), digital ;24 cm.

Olesja Rissling analyzes the potential interaction of mycophenolic acid (MPA) and pantoprazole. MPA is used as an immunosuppressive drug to prevent acute organ rejections after organ transplantation. Pantoprazole, known to interact with the bioavailability of drugs, is used to prevent upper gastrointestinal disorders. The author performed a clinical pharmacokinetic study in renal transplant patients to evaluate a potential interaction of MPA and pantoprazole. The bioavailability and the maximum concentration of MPA were determined with or without pantoprazole intake. An influence on the immunosuppressive effect was evaluated by measuring the target enzyme activity. Overall, no significant change in the bioavailability or the maximum concentration was found. Similar results were obtained for the target enzyme activity after pantoprazole intake with MPA. The results suggest that the interaction of pantoprazole with MPA does not compromise the immunosuppressive effect to a clinically meaningful extent. Contents Validation of an Assay for Quantification of MPA and MPAG Clinical Study of a PK Interaction of Pantoprazole and MPA Bioequivalence Analysis Target Groups Researchers and students in the fields of medicine and pharmacy Practitioners in the fields of nephrology and clinical pharmacology The Author Olesja Rissling studied pharmacy and works as a research associate at the Federal Joint Committee in the field of benefit assessment of pharmaceuticals.

ISBN: 9783658198893

Standard No.: 10.1007/978-3-658-19889-3doiSubjects--Topical Terms:

1197012
Mycophenolic acid.

LC Class. No.: RM373

Dewey Class. No.: 615.37

Interaction of mycophenolic acid and pantoprazole = a pharmacokinetic crossover study /
LDR:02441nam a2200301 a 4500 001 921830
003 DE-He213
005 20180511133521.0
006 m d
007 cr nn 008maaau
008 190624s2017 gw s 0 eng d
020 $a 9783658198893 $q (electronic bk.)
020 $a 9783658198886 $q (paper)
024 7 $a 10.1007/978-3-658-19889-3 $2 doi
035 $a 978-3-658-19889-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RM373
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 615.37 $2 23
090 $a RM373 $b .R596 2017
100 1 $a Rissling, Olesja. $3 1197011
245 1 0 $a Interaction of mycophenolic acid and pantoprazole $h [electronic resource] : $b a pharmacokinetic crossover study / $c by Olesja Rissling.
260 $a Wiesbaden : $b Springer Fachmedien Wiesbaden : $b Imprint: Springer Spektrum, $c 2017.
300 $a xxii, 162 p. : $b ill. (some col.), digital ; $c 24 cm.
520 $a Olesja Rissling analyzes the potential interaction of mycophenolic acid (MPA) and pantoprazole. MPA is used as an immunosuppressive drug to prevent acute organ rejections after organ transplantation. Pantoprazole, known to interact with the bioavailability of drugs, is used to prevent upper gastrointestinal disorders. The author performed a clinical pharmacokinetic study in renal transplant patients to evaluate a potential interaction of MPA and pantoprazole. The bioavailability and the maximum concentration of MPA were determined with or without pantoprazole intake. An influence on the immunosuppressive effect was evaluated by measuring the target enzyme activity. Overall, no significant change in the bioavailability or the maximum concentration was found. Similar results were obtained for the target enzyme activity after pantoprazole intake with MPA. The results suggest that the interaction of pantoprazole with MPA does not compromise the immunosuppressive effect to a clinically meaningful extent. Contents Validation of an Assay for Quantification of MPA and MPAG Clinical Study of a PK Interaction of Pantoprazole and MPA Bioequivalence Analysis Target Groups Researchers and students in the fields of medicine and pharmacy Practitioners in the fields of nephrology and clinical pharmacology The Author Olesja Rissling studied pharmacy and works as a research associate at the Federal Joint Committee in the field of benefit assessment of pharmaceuticals.
650 0 $a Mycophenolic acid. $3 1197012
650 0 $a Drug interactions. $3 769349
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Pharmacology/Toxicology. $3 593882
650 2 4 $a Laboratory Medicine. $3 673604
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-658-19889-3
950 $a Biomedical and Life Sciences (Springer-11642)